CN110742968A - External chloasma medicament containing peony whole plant extract and preparation method thereof - Google Patents
External chloasma medicament containing peony whole plant extract and preparation method thereof Download PDFInfo
- Publication number
- CN110742968A CN110742968A CN201911145752.6A CN201911145752A CN110742968A CN 110742968 A CN110742968 A CN 110742968A CN 201911145752 A CN201911145752 A CN 201911145752A CN 110742968 A CN110742968 A CN 110742968A
- Authority
- CN
- China
- Prior art keywords
- extract
- peony
- whole plant
- prepared
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Abstract
The invention discloses an external medicine containing peony whole plant extract for treating chloasma and a preparation method thereof, wherein the external medicine is prepared from the following components in parts by weight: 30-60 g of a peony whole plant extract, 10-20 g of a bletilla striata extract, 10-20 g of a white poria extract, 10-20 g of a Japanese ampelopsis extract, 10-20 g of a avocado extract, 10-20 g of a prinsepia utilis royle extract, 10-20 g of arbutin, 10-20 g of tranexamic acid, 10-20 g of nicotinamide, 100-200 g of sodium hyaluronate, 100-200 g of allantoin and 100-200 g of butanediol; the peony whole plant extract is prepared by mixing a moutan bark extract, a peony flower extract and a peony leaf extract according to a mass ratio of 1:1: 1. The invention has the functions of whitening and fading spots, repairing skin barriers and moistening, is mainly used for treating and nursing chloasma, pigmentation and skin dullness, and has obvious curative effect through clinical test verification.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an external chloasma medicament containing a peony whole plant extract and a preparation method thereof.
Background
Chloasma is a common pigmentary abnormal skin disease in clinic. The traditional Chinese medicine considers that the chloasma is caused by spleen dampness and kidney deficiency, qi and blood stasis stagnation and face nourishing failure, and the treatment mainly comprises dredging qi activity, activating blood and dissolving stasis. The western medicine considers that the pathogenesis of chloasma is complex, and the skin photoaging and estrogen stimulation induced by chronic ultraviolet exposure and the like can be main pathogenic factors. The treatment mainly comprises inhibiting melanin formation and transport. At present, a few external medicines for treating chloasma are available, and a common medicine is hydroquinone cream, but the hydroquinone cream has the disadvantages of undesirable curative effect, long administration time, obvious side effect, high medical expense, complex production process and high production cost.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide an external chloasma medicament containing a peony whole plant extract and a preparation method thereof. In order to achieve the above purpose, the invention adopts the following technical scheme:
a chloasma external use medicine containing peony whole plant extract is prepared by the following components by weight:
30-60 g of a peony whole plant extract, 10-20 g of a bletilla striata extract, 10-20 g of a white poria extract, 10-20 g of a Japanese ampelopsis extract, 10-20 g of a avocado extract, 10-20 g of a prinsepia utilis royle extract, 10-20 g of arbutin, 10-20 g of tranexamic acid, 10-20 g of nicotinamide, 100-200 g of sodium hyaluronate, 100-200 g of allantoin and 100-200 g of butanediol; the peony whole plant extract is prepared by mixing a moutan bark extract, a peony flower extract and a peony leaf extract according to a mass ratio of 1:1: 1.
Further, the paint is prepared from the following components in parts by weight: 30g of a peony whole plant extract, 10g of a common bletilla pseudobulb extract, 10g of a white poria extract, 10g of a Japanese ampelopsis root extract, 10g of a avocado extract, 10g of a prinsepia utilis royle extract, 10g of arbutin, 10g of tranexamic acid, 10g of nicotinamide, 100g of sodium hyaluronate, 100g of allantoin and 100g of butanediol; the peony whole plant extract is formed by mixing 10g of a moutan bark extract, 10g of a peony flower extract and 10g of a peony leaf extract.
Further, the paint is prepared from the following components in parts by weight: 45g of a peony whole plant extract, 15g of a common bletilla pseudobulb extract, 15g of a white poria extract, 15g of a Japanese ampelopsis extract, 15g of a avocado extract, 15g of a prinsepia utilis royle extract, 15g of arbutin, 15g of tranexamic acid, 15g of nicotinamide, 150g of sodium hyaluronate, 150g of allantoin and 150g of butanediol; the peony whole plant extract is formed by mixing 15g of moutan bark extract, 15g of peony flower extract and 15g of peony leaf extract.
Further, the paint is prepared from the following components in parts by weight: 60g of a peony whole plant extract, 20g of a common bletilla pseudobulb extract, 20g of a white poria extract, 20g of a Japanese ampelopsis root extract, 20g of a avocado extract, 20g of a prinsepia utilis royle extract, 20g of arbutin, 20g of tranexamic acid, 20g of nicotinamide, 200g of sodium hyaluronate, 200g of allantoin and 200g of butanediol; the peony whole plant extract is prepared by mixing 20g of moutan bark extract, 20g of peony flower extract and 20g of peony leaf extract.
A preparation method of an external medicine containing a peony whole plant extract for treating chloasma specifically comprises the following steps:
a. weighing equivalent moutan bark extract, peony flower extract, peony leaf extract, bletilla striata extract, white poria extract, radix ampelopsis extract, avocado extract and prinsepia utilis royle extract according to the proportion, mixing, adding 100-degree purified water, stirring for dissolving, stirring uniformly, filtering, and taking filtrate for later use;
b. weighing arbutin, tranexamic acid, nicotinamide, sodium hyaluronate, allantoin and butanediol according to a ratio, adding into 100-degree purified water, stirring for dissolving, and stirring uniformly to obtain a filtrate for later use;
c. weighing the filtrate prepared in the step a and the filtrate prepared in the step b according to the weight ratio of 1:1, mixing, heating to 45-50 ℃, and uniformly mixing to obtain the product.
In the invention, the moutan bark extract, the peony flower extract, the peony leaf extract, the bletilla striata extract, the white poria extract, the ampelopsis japonica extract, the avocado extract and the prinsepia utilis royle extract are prepared by adopting a supercritical carbon dioxide extraction method.
In the invention, the moutan bark extract can inhibit the generation of free radicals in cells, whiten the skin, reduce and discolor deposited pigments in the skin, remove blood stasis and spots, relieve swelling and pain, resist allergy, resist viruses and the like; the peony flower extract and the peony leaf extract have the effects of nourishing blood, removing blood stasis, promoting microcirculation, whitening skin, removing freckles, resisting allergy, inhibiting bacteria and diminishing inflammation; rhizoma Bletillae extract has effects of detumescence, granulation promotion, skin whitening and speckle reduction; the radix Ampelopsis extract has effects of clearing heat, dispelling pathogenic wind, whitening skin and removing speckle; the Poria cocos wolf extract has the effects of removing freckles, whitening skin and moistening skin; the avocado extract has the effects of repairing skin barriers, regulating and improving the fluidity viscosity of the product and improving the use texture of the product, and is a very good softener and skin conditioner; the Prinsepia utilis Royle extract can prevent pigmentation, repair damaged skin, improve rough skin and compact skin; arbutin is extracted from the leaves of bearberry to inhibit the activity of melanocyte tyrosinase, thereby preventing the production of melanin and reducing skin pigmentation; tranexamic acid interferes with the association between melanocytes and keratinocytes by inhibiting the conversion of plasminogen to plasmin, thereby reducing melanin production and transport within melanocytes; niacinamide activates cyclic 3,5 nucleotide phosphodiesterase, decomposing melanocyte-stimulating 3, 5-cyclic adenosine monophosphate into adenine-5-monophosphate, thereby reducing melanin production and promoting the exfoliation of melanin-containing keratinocytes; sodium hyaluronate and allantoin have the functions of repairing skin barrier and powerful skin moisturizing; the butanediol has effects of small molecule deep moisture keeping and antibacterial.
Due to the adoption of the technical scheme, the invention has the following advantages:
the invention has the functions of whitening and fading spots, repairing skin barriers and moistening, is mainly used for treating and nursing chloasma, pigmentation and skin dullness, and has obvious curative effect through clinical test verification.
Detailed Description
The technical solution of the present invention will be described in further detail with reference to examples.
In the case of the example 1, the following examples are given,
a chloasma external use medicine containing peony whole plant extract is prepared by the following components by weight: 10g of moutan bark extract, 10g of peony flower extract, 10g of peony leaf extract, 10g of bletilla striata extract, 10g of white poria extract, 10g of radix ampelopsis extract, 10g of avocado extract, 10g of prinsepia utilis royle extract, 10g of arbutin, 10g of tranexamic acid, 10g of nicotinamide, 100g of sodium hyaluronate, 100g of allantoin and 100g of butanediol.
The preparation method of the externally applied chloasma medicament containing the peony whole plant extract specifically comprises the following steps:
a. weighing 10g of moutan bark extract, 10g of peony flower extract, 10g of peony leaf extract, 10g of bletilla striata extract, 10g of white poria extract, 10g of radix ampelopsis extract, 10g of avocado extract and 10g of prinsepia utilis royle extract, mixing, adding 800ml of 100-DEG purified water, stirring for dissolving, stirring uniformly, filtering, and taking filtrate for later use;
b. weighing 10g of arbutin, 10g of tranexamic acid, 10g of nicotinamide, 100g of sodium hyaluronate, 100g of allantoin and 100g of butanediol according to a ratio, adding 2000ml of 100-DEG purified water, stirring and dissolving, and uniformly stirring to obtain a filtrate for later use;
c. weighing the filtrate prepared in the step a and the filtrate prepared in the step b according to the weight ratio of 1:1, mixing, heating to 45-50 ℃, and uniformly mixing to obtain the product.
Example 2
A chloasma external use medicine containing peony whole plant extract is prepared by the following components by weight: 15g of moutan bark extract, 15g of peony flower extract, 15g of peony leaf extract, 15g of bletilla striata extract, 15g of white poria extract, 15g of radix ampelopsis extract, 15g of avocado extract, 15g of prinsepia utilis royle extract, 15g of arbutin, 15g of tranexamic acid, 15g of nicotinamide, 150g of sodium hyaluronate, 150g of allantoin and 150g of butanediol.
The preparation method of the externally applied chloasma medicament containing the peony whole plant extract specifically comprises the following steps:
a. weighing 15g of moutan bark extract, 15g of peony flower extract, 15g of peony leaf extract, 15g of bletilla striata extract, 15g of white poria extract, 15g of radix ampelopsis extract, 15g of avocado extract and 15g of prinsepia utilis royle extract, mixing, adding 1200ml of 100-degree purified water, stirring for dissolving, stirring uniformly, filtering, and taking filtrate for later use;
b. weighing 15g of arbutin, 15g of tranexamic acid, 15g of nicotinamide, 150g of sodium hyaluronate, 150g of allantoin and 150g of butanediol according to a ratio, adding 3000ml of 100-DEG purified water, stirring and dissolving, and uniformly stirring to obtain a filtrate for later use;
c. weighing the filtrate prepared in the step a and the filtrate prepared in the step b according to the weight ratio of 1:1, mixing, heating to 45-50 ℃, and uniformly mixing to obtain the product.
Example 3
A chloasma external use medicine containing peony whole plant extract is prepared by the following components by weight: 20g of moutan bark extract, 20g of peony flower extract, 20g of peony leaf extract, 20g of bletilla striata extract, 20g of white poria extract, 20g of ampelopsis japonica extract, 20g of avocado extract, 20g of prinsepia utilis royle extract, 20g of arbutin, 20g of tranexamic acid, 20g of nicotinamide, 200g of sodium hyaluronate, 200g of allantoin and 200g of butanediol.
The preparation method of the externally applied chloasma medicament containing the peony whole plant extract specifically comprises the following steps:
a. weighing 20g of moutan bark extract, 20g of peony flower extract, 20g of peony leaf extract, 20g of bletilla striata extract, 20g of white poria extract, 20g of ampelopsis japonica extract, 20g of avocado extract and 20g of prinsepia utilis royle extract, mixing, adding 1600ml of 100-DEG purified water, stirring for dissolving, stirring uniformly, filtering, and taking filtrate for later use;
b. weighing 20g of arbutin, 20g of tranexamic acid, 20g of nicotinamide, 200g of sodium hyaluronate, 200g of allantoin and 200g of butanediol according to a ratio, adding 4000ml of 100-DEG purified water, stirring and dissolving, and uniformly stirring to obtain a filtrate for later use;
c. weighing the filtrate prepared in the step a and the filtrate prepared in the step b according to the weight ratio of 1:1, mixing, heating to 45-50 ℃, and uniformly mixing to obtain the product.
The following tests were carried out on the compound external preparations prepared in examples 1, 2 and 3, as follows:
test 1, acute toxicity test in mice
According to the result of the preliminary test, a horns method is adopted, 4 dosage groups of 21500, 10000, 4640 and 2150/kg are set, the experimental animal selects Kunming white mice with the weight of 18-22 g, each dosage group comprises 10 animals, and each half of the animals are female and male, the test object is given by a gavage method, the gavage volume is calculated according to 0.4mL/10g of the body weight, and the actual non-toxicity level of the acute toxicity is observed for two weeks.
Test 2, multiple skin irritation test
The method comprises the following steps of adopting a multiple skin irritation test method, using 4 healthy adult white rabbits with the weight of 2-2.5 Kg for experimental animals, shearing off hairs on two sides of the spine of the rabbits 24 hours before the experiment, wherein the left side and the right side of the hair removal range are 3 multiplied by 3 square centimeters, and applying 0.5mL of the compound external medicine prepared in the embodiment 1/the embodiment 2/the embodiment 3 on the skin with the hairs removed on the left side of the rabbits, once per day and continuously applying for 14 days; the right unhaired skin was smeared with distilled water as control; the skin reaction is observed every day, and the skin at the smearing part is taken for pathological and histological examination after the experiment is finished.
The test result shows that all tested skins have no skin irritation reaction such as erythema, edema, desquamation and the like, the integral of multiple skin irritation indexes is zero, the pathological histological examination shows that no pathological change is found in epidermis and dermis, and the integral of the pathological histological examination is zero.
The skin irritation test is evaluated according to evaluation criteria of multiple skin irritation tests, and has no irritation to the skin.
Test 3, one-time skin irritation test
Adopting a skin irritation test method for one time, wherein 4 healthy adult white rabbits with the weight of 2-2.5 Kg are selected as experimental animals; shearing off hairs on two sides of the spine of the back of the rabbit 24 hours before the test, wherein the left side and the right side of the hair removing range are 3 multiplied by 3 square centimeters; 0.5mL of the compound external medicine prepared in the embodiment 1/embodiment 2/embodiment 3 is dropped on four layers of gauze with the size of 2.5 multiplied by 2.5c m, and is applied to the unhaired skin at the left side of the rabbit, and then is covered by a layer of cellophane and is fixed by adhesive plaster to be used as a test group; the right unhaired skin was applied with distilled four-layer gauze as a control; the application was carried out for 6 hours and the skin local reaction was observed at 4, 24 and 48 hours after removal of the gauze.
Test results, 4, 24 and 48 hours after removal of the gauze, no erythema and edema were formed on the skin of the test group and the control group locally, and the primary skin irritation response intensity was scored as 0.
The skin irritation effect of the rabbit is not stimulated according to evaluation standards of skin irritation intensity.
Test 4, eye irritation test
4 healthy adult rabbits were used, and the compound external preparation prepared in example 1/example 2/example 3 was dropped into the conjunctival sac of one side of the rabbit, and two drops were dropped to prepare a test group; dropping distilled water to the other side of the eye to serve as a control group; rabbit eyes were examined for damage and recovery to conjunctiva, iris and cornea at 6, 24, 48 hours and 4, 7 days after eye dropping.
As a result: no eye irritation reaction such as conjunctiva, iris congestion, edema and secretion of the test group and the control group was observed in a predetermined period of time, and corneal opacity was not observed. The acute eye irritation integral index is zero.
Example 1/example 2/example 3 are non-irritating to the eyes according to the evaluation criteria for the intensity of eye irritation.
Clinical observations were made of the topical drugs prepared in example 1, example 2 and example 3:
selecting 65 patients with chloasma faciei, and randomly dividing into 35 patients in a treatment group and 30 patients in a control group; the treatment group used the topical medicine of example 1/example 2/example 3, and applied to the affected part 2 times a day in the morning and evening for 4 weeks; the control group applied hydroquinone cream to affected part 2 times a day for 4 weeks; the results show that: the treatment group is cured by 13 cases, 15 cases with obvious effect, 7 cases with effect and 0 case with no effect, and the obvious effect rate is 80.00 percent. The control group is cured for 3 cases, the obvious effect is 7 cases, the effective 18 cases and the ineffective 2 cases, the obvious effect rate is 33.33 percent, and the difference of the obvious effect rates of the treatment group and the control group has statistical significance (P is less than 0.05).
As can be seen from the table above, the external medicine of the invention has obvious curative effect on chloasma.
Claims (5)
1. The externally applied medicine for treating chloasma containing a peony whole plant extract is characterized by being prepared from the following components in parts by weight:
30-60 g of a peony whole plant extract, 10-20 g of a bletilla striata extract, 10-20 g of a white poria extract, 10-20 g of a Japanese ampelopsis extract, 10-20 g of a avocado extract, 10-20 g of a prinsepia utilis royle extract, 10-20 g of arbutin, 10-20 g of tranexamic acid, 10-20 g of nicotinamide, 100-200 g of sodium hyaluronate, 100-200 g of allantoin and 100-200 g of butanediol; the peony whole plant extract is prepared by mixing a moutan bark extract, a peony flower extract and a peony leaf extract according to a mass ratio of 1:1: 1.
2. The external medicine containing the peony whole plant extract for treating chloasma according to claim 1, which is prepared from the following components in parts by weight:
30g of a peony whole plant extract, 10g of a bletilla striata extract, 10g of a white poria extract, 10g of a Japanese ampelopsis extract, 10g of a avocado extract, 10g of a prinsepia utilis royle extract, 10g of arbutin, 10g of tranexamic acid, 10g of nicotinamide, 100g of sodium hyaluronate, 100g of allantoin and 100g of butanediol; the peony whole plant extract is formed by mixing 10g of a moutan bark extract, 10g of a peony flower extract and 10g of a peony leaf extract.
3. The external medicine containing the peony whole plant extract for treating chloasma according to claim 1, which is prepared from the following components in parts by weight:
45g of a peony whole plant extract, 15g of a common bletilla pseudobulb extract, 15g of a white poria extract, 15g of a Japanese ampelopsis extract, 15g of a avocado extract, 15g of a prinsepia utilis royle extract, 15g of arbutin, 15g of tranexamic acid, 15g of nicotinamide, 150g of sodium hyaluronate, 150g of allantoin and 150g of butanediol; the peony whole plant extract is formed by mixing 15g of moutan bark extract, 15g of peony flower extract and 15g of peony leaf extract.
4. The external medicine containing the peony whole plant extract for treating chloasma according to claim 1, which is prepared from the following components in parts by weight:
60g of a peony whole plant extract, 20g of a common bletilla pseudobulb extract, 20g of a white poria extract, 20g of a Japanese ampelopsis root extract, 20g of a avocado extract, 20g of a prinsepia utilis royle extract, 20g of arbutin, 20g of tranexamic acid, 20g of nicotinamide, 200g of sodium hyaluronate, 200g of allantoin and 200g of butanediol; the peony whole plant extract is prepared by mixing 20g of moutan bark extract, 20g of peony flower extract and 20g of peony leaf extract.
5. The preparation method of the external medicine for treating chloasma, which contains the peony whole plant extract, is characterized by comprising the following steps of:
a. weighing equivalent moutan bark extract, peony flower extract, peony leaf extract, bletilla striata extract, white poria extract, radix ampelopsis extract, avocado extract and prinsepia utilis royle extract according to the proportion, mixing, adding 100-degree purified water, stirring for dissolving, stirring uniformly, filtering, and taking filtrate for later use;
b. weighing arbutin, tranexamic acid, nicotinamide, sodium hyaluronate, allantoin and butanediol according to a ratio, adding into 100-degree purified water, stirring for dissolving, and stirring uniformly to obtain a filtrate for later use;
c. weighing the filtrate prepared in the step a and the filtrate prepared in the step b according to the weight ratio of 1:1, mixing, heating to 45-50 ℃, and uniformly mixing to obtain the product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911145752.6A CN110742968A (en) | 2019-11-21 | 2019-11-21 | External chloasma medicament containing peony whole plant extract and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911145752.6A CN110742968A (en) | 2019-11-21 | 2019-11-21 | External chloasma medicament containing peony whole plant extract and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110742968A true CN110742968A (en) | 2020-02-04 |
Family
ID=69283984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911145752.6A Pending CN110742968A (en) | 2019-11-21 | 2019-11-21 | External chloasma medicament containing peony whole plant extract and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110742968A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494262A (en) * | 2020-04-27 | 2020-08-07 | 渠志灿 | Peony extract and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142431A (en) * | 2013-02-19 | 2013-06-12 | 河南科技大学 | Tree peony hydrolat |
-
2019
- 2019-11-21 CN CN201911145752.6A patent/CN110742968A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142431A (en) * | 2013-02-19 | 2013-06-12 | 河南科技大学 | Tree peony hydrolat |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494262A (en) * | 2020-04-27 | 2020-08-07 | 渠志灿 | Peony extract and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4125366B2 (en) | Hygiene and cosmetic preparations for preventing and treating skin diseases and methods for obtaining the same | |
| WO2018082116A1 (en) | External traditional chinese medicine composition and skin care preparation having effect of whitening and freckle-removing | |
| CN108653129B (en) | Skin dressing containing natural plant anti-allergy composition | |
| CN103142856A (en) | Traditional Chinese medicine whitening and freckle removing liquid | |
| CN103635200A (en) | Hyaluronic acid decomposition inhibitor comprising rosemary extract and retinol acetate | |
| CN104784296B (en) | One kind resists allergic composition and application thereof | |
| CN104784297B (en) | One kind resists allergic composition | |
| CN110742968A (en) | External chloasma medicament containing peony whole plant extract and preparation method thereof | |
| US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
| CN111166707B (en) | Facial anti-aging repairing and nursing composition and preparation method and application thereof | |
| CN106039022B (en) | Skin-brightening and whitening traditional Chinese medicine composition, skin-brightening and whitening traditional Chinese medicine preparation, skin-brightening and whitening mask and preparation method | |
| CN102335231B (en) | Chinese medicinal moisturizing cream for treating chloasma as well as preparation method and application thereof | |
| CN110731933A (en) | allergy-relieving, moisturizing and anti-aging hand cream containing peony whole plant extract and preparation method thereof | |
| CN107184528B (en) | Whitening emulsion and preparation method thereof | |
| CN112057388A (en) | Cream for striae gravidarum repair and preparation method thereof | |
| KR100552307B1 (en) | The cosmetic materials of adding a composite extracted from chinese medicine mterias having effect of antiageing | |
| CN110876778A (en) | External use medicine for treating hyperhidrosis containing peony whole plant extract and preparation method thereof | |
| KR102420354B1 (en) | Lotion composition having circulation and vitality and the manufacturing method thereof | |
| CN114053329B (en) | Application of broussonetia papyrifera polysaccharide in preparation of medicines or sunscreen cosmetics for preventing and treating ultraviolet injury | |
| EP4085913A1 (en) | Formulation comprising nicotinamide, zinc, copper and glutathione for treating acne rosacea | |
| CN104983769A (en) | Medicine for treating epifolliculitis | |
| CN1100527C (en) | Skin health-care lotion | |
| CN106138930B (en) | A lotion containing Chinese medicinal effective components for treating ichthyosis, and its preparation method | |
| CN117017854A (en) | Chinese herbal medicine mask compound with functions of maintaining beauty and keeping young | |
| KR20220001749A (en) | Functional mask pack containing functional compositions based on ceramide np |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200204 |
|
| RJ01 | Rejection of invention patent application after publication |